A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Tarlatamab (Primary) ; Pembrolizumab
- Indications Carcinoma; Small cell lung cancer
- Focus Adverse reactions; First in man
- Acronyms DeLLphi 300
- Sponsors Amgen
- 11 Jun 2024 Planned End Date changed from 21 Oct 2025 to 18 Oct 2025.
- 11 Jun 2024 Planned primary completion date changed from 22 Oct 2024 to 18 Oct 2024.
- 29 Mar 2024 Results (As of March 28, 2023, n=202) of pharmacokinetics presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics